Chengdu Majiazi Biotechnology

Chengdu Magis Biotechnology is a Chinese biotechnology company focused on the development of innovative recombinant protein drugs and vaccines. Founded in 2021 by Dr. Song Xu, a professor at Sichuan University, the company leverages a proprietary protein expression and purification platform to target various indications, including infectious diseases and oncology. The company is headquartered in the Chengdu Medical City and has received significant early-stage investment, including a Pre-A round led by GL Capital. Its core technology aims to improve the stability and efficacy of complex protein therapeutics for global markets. The firm's pipeline includes several recombinant protein candidates currently in the pre-clinical and IND-enabling stages.